Skip Navigation

Rheumatology 2005 44(2):141-142; doi:10.1093/rheumatology/keh474
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Black, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Black, C.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 2 © British Society for Rheumatology 2005; all rights reserved

EDITORIAL

Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?

C. Black

Carol M Black CBE MRCP, Centre for Rheumatology, Professor of Rheumatology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF. E-mail: c.black@medsch.ucl.ac.uk

The first 10% of the full text of this article appears below.

Pulmonary arterial hypertension (PAH) is a rapidly progressive disorder that is lethal if it remains undiagnosed and untreated. However, modern treatments represent a tremendous advance upon the therapies available just a few years ago and the prognosis for this life-threatening disease has changed. There is now good reason to ensure earlier diagnosis of PAH among systemic sclerosis (scleroderma) patients.

PAH is defined as a mean pulmonary artery pressure (PAP) exceeding 25 mmHg at rest or 30 mmHg during exercise. If left untreated between 45 and 60% of patients with PAH will die within 2 yr of diagnosis [1]. However, when it occurs as a manifestation of scleroderma PAH is particularly severe and 1-yr survival following diagnosis is approximately 55% [2]. Since scleroderma . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?